The p53 protein is one of the body's most critical defenses against cancer, acting as a tumor suppressor that stops cells from dividing uncontrollably. When the gene responsible for this protein mutates, it drives the development of about half of all human cancers. Because these mutations occur early and are present in almost every cell of a growing tumor, they should act as massive red flags for the immune system. However, tumors have evolved sophisticated ways to remain invisible to circulating T cells, making these ubiquitous mutations surprisingly difficult for the body to target. ​A recent breakthrough published in the journal Immunity by researchers at the Dana-Farber Cancer Institute uncovers exactly how these cancer cells fly under the radar. Immune cells rely on scanning the surface of other cells for tiny protein fragments, which act like a molecular window display showing what is happening inside. By using advanced mass spectrometry to examine this display, scientists discovered that mutant p53 fragments are almost completely missing from the surface of cancer cells. ​The research team identified distinct cellular tactics responsible for this disappearing act. In some tumors, cancer cells overactivate a destructive enzyme called ERAP1 that aggressively shreds the mutant p53 fragment before it can ever be transported to the cell surface. In other scenarios, the mutant protein fragment is so structurally unstable that it cannot securely attach to the cell's surface receptors, causing the target to degrade before a T cell can lock onto it. Both strategies leave highly capable immune cells wandering past the tumor without recognizing the disease. ​Understanding these evasion mechanisms opens a completely new therapeutic avenue for oncology. The researchers propose an approach called an immunopeptidome shift, which involves using specialized drugs to force cancer cells to alter their surface display. By chemically blocking the shredding enzymes or stabilizing the weak surface connections, future treatments could deliberately expose the hidden p53 mutations. Stripping away this molecular camouflage would reveal the true nature of the tumor, leaving the entire cancer vulnerable to a coordinated and effective immune attack. Paper details: Koji Haratani et al, Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection, Immunity (2026). DOI: 10.1016/j.immuni.2026.08.011